CBLL vs ACLS vs ONTO vs NVCR

For growth investors, CeriBell, Inc.

(CBLL) is the stronger pick with 36. 1% revenue growth year-over-year, versus -17. 6% for Axcelis Technologies, Inc. (ACLS). Axcelis Technologies, Inc. (ACLS) offers the better valuation at 42. 9x trailing P/E (44. 7x forward), making it the more compelling value choice. Analysts rate CeriBell, Inc. (CBLL) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Axcelis Technologies, Inc.

(ACLS) is the cheapest at 42. 9x versus Onto Innovation Inc. at 102. 4x. On forward P/E, Onto Innovation Inc. is actually cheaper at 39. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Onto Innovation Inc. wins at 1. 16x versus Axcelis Technologies, Inc. 's 2. 12x — a reasonable growth-adjusted valuation.

Over the past 5 years, Onto Innovation Inc.

(ONTO) delivered a total return of +360. 4%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ACLS returned +1550% versus CBLL's -19. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CeriBell, Inc.

(CBLL) is the lower-risk stock at 1. 61β versus Onto Innovation Inc. 's 2. 60β — meaning ONTO is approximately 61% more volatile than CBLL relative to the S&P 500. On balance sheet safety, Onto Innovation Inc. (ONTO) carries a lower debt/equity ratio of 1% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CeriBell, Inc.

(CBLL) is pulling ahead at 36. 1% versus -17. 6% for Axcelis Technologies, Inc. (ACLS). On earnings-per-share growth, the picture is similar: CeriBell, Inc. grew EPS 56. 9% year-over-year, compared to -38. 2% for Axcelis Technologies, Inc.. Over a 3-year CAGR, CBLL leads at 50. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Axcelis Technologies, Inc.

(ACLS) is the more profitable company, earning 14. 3% net margin versus -60. 0% for CeriBell, Inc. — meaning it keeps 14. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACLS leads at 14. 2% versus -65. 6% for CBLL. At the gross margin level — before operating expenses — CBLL leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Onto Innovation Inc. (ONTO) is the more undervalued stock at a PEG of 1. 16x versus Axcelis Technologies, Inc. 's 2. 12x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Onto Innovation Inc. (ONTO) trades at 39. 9x forward P/E versus 44. 7x for Axcelis Technologies, Inc. — 4. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Axcelis Technologies, Inc.

(ACLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1550% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLS: +1550%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CBLL (Healthcare) and ACLS (Technology) and ONTO (Technology) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CBLL is a small-cap high-growth stock; ACLS is a small-cap quality compounder stock; ONTO is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.